demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID 19 outpatients
neutralizing antibody
bamlanivimab monotherapy BLAZE-1 phase 2 ...
bamlanivimab/etesevimab BLAZE-1 phase 2 ... BLAZE-1 phase 3 ...
casirivimab/imdevimab (Ronapreve) Cov-2067 Weinreich ... Cov-2069 ...
sotrovimab (Xevudy; VIR-7831) COMET-ICE

12 studies excluded by filtering options 0

5570 CT-P59 1.2, 2020 210excludedrisk of bias not avaialble
6137 CT-P59 3.2 part 1, 2021 110risk of bias not avaialble
6456 ACTIV-2 (BRII-196 and BRII-198), 0 110risk of bias not avaialble
6528 BLAZE-4, 0 110risk of bias not avaialble
6672 TACKLE, 0 110risk of bias not avaialble
6708 Webb, 2021 0130selection pending
6920 Rainwater-Lovett, 2021 0130selection pending
6921 Bariola, 2021 1130not a RCTrisk of bias not avaialble
7021 BLAZE 4 LY-CoV1404, 0 110risk of bias not avaialble
8968 OPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab), 2021 113high risk of bias
9265 OPTIMISE-C19 (bamlanivimab monotherapy vs casirivimab-imdevimab), 2021 010selection pending
9266 CT-P59 3.2 part 2, 2021 110risk of bias not avaialble